Home
Search

Press Releases

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Featured Press Releases
BIO Statement on Changes Announced to the U.S…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO)  released the following statement on changes announced to the US childhood vaccine schedule.“American health is as unique as America itself…
Learn more
BIO Statement on December 2025 ACIP Meeting
WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Head of Health Policy and Programs of the Biotechnology Innovation Organization (BIO) released the following statement on the December 2025 ACIP meeting.“For decades, the CDC’s Advisory…
Learn more
BIO Statement on the Retirement of Richard Pazdur…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA.“Dr. Pazdur has dedicated decades of his career…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
BIO Applauds Introduction of Bipartisan ORPHAN Cures Act
February 5, 2025
Urges Congress to support rare disease patients & support the billWASHINGTON, D.C. (February 5, 2025) – John F. Crowley, President & CEO of the Biotechnology Innovation Organization (BIO), today released the following statement after…
BIO Statement on New List of Medicines Targeted for Government Price Setting
January 17, 2025
WASHINGTON, D.C. (January 17, 2025) – The Biotechnology Innovation Organization (BIO) today released the following statement after the Biden administration released a list of 15 medicines being selected for government price setting:“In the final…
BIO Statement on the USMCA Biotech Corn Dispute Panel’s Final Ruling
December 20, 2024
Today the dispute settlement panel formed under the United States-Mexico-Canada Agreement (USMCA) issued a final ruling related to Mexico's restrictions on the importation of genetically modified (GM) corn. In response, John Crowley, President…
BIO Applauds the Inclusion of Important Health Care and Agriculture Priorities and Programs in Year-end Government Funding Bill
December 17, 2024
John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), today released the following statement ahead of an expected vote in the U.S. House of Representatives on a year-end government funding bill that includes many…
BIO Appoints Veteran Communications Leader Sarah Alspach as Executive Vice President and Chief Communications Officer
December 9, 2024
Today, the Biotechnology Innovation Organization (BIO) named Sarah Alspach as its new executive vice president and chief communications officer. Alspach, a communications veteran, will join BIO’s senior leadership team. Her first day will be…
New Report Finds Bioscience Sector Generates Over $3 Trillion for U.S. Economy
December 2, 2024
Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic performance, its impacts, and its geographic…
BIO Statement Regarding Nomination of Robert F. Kennedy Jr.
November 14, 2024
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
BIO Released the Following Statement After Yesterday’s Announcement From the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) Sharing Its Final Notice Exemption for Additional Modification Plants
November 13, 2024
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO Statement on Lawsuit Over 340B Rebates
November 12, 2024
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…
BIO Statement on 2024 U.S. Election
November 6, 2024
WASHINGTON – BIO President & CEO John F. Crowley released the following statement on the results of the 2024 U.S. election:“We look forward to working closely with President-elect Trump, his incoming Administration, and members of Congress on…
gooddaybio-cover-final
Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy. 

Sign Up Today